Annual CFI
-$528.00 K
-$36.98 M-101.45%
31 December 2023
Summary:
AcelRx Pharmaceuticals annual cash flow from investing activities is currently -$528.00 thousand, with the most recent change of -$36.98 million (-101.45%) on 31 December 2023. During the last 3 years, it has risen by +$25.59 million (+97.98%).ACRX Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFI
-$3.65 M
-$3.65 M-100.00%
31 December 2023
Summary:
AcelRx Pharmaceuticals quarterly cash flow from investing activities is currently -$3.65 million, with the most recent change of -$3.65 million (-100.00%) on 31 December 2023.ACRX Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFI
-$528.00 K
-$6.31 M-109.13%
31 December 2023
Summary:
AcelRx Pharmaceuticals TTM cash flow from investing activities is currently -$528.00 thousand, with the most recent change of -$6.31 million (-109.13%) on 31 December 2023.ACRX TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ACRX Cash From Investing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | - | - |
| 3 y3 years | +98.0% | +17.8% | +98.0% |
| 5 y5 years | +98.6% | -153.0% | +98.6% |
ACRX Cash From Investing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | ||||||
| 5 y | 5 years | ||||||
| alltime | all time | -101.4% | -116.1% | -101.4% |
AcelRx Pharmaceuticals Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2023 | -$528.00 K(-101.4%) | -$3.65 M(<-9900.0%) | -$528.00 K(-109.1%) |
| Sept 2023 | - | $0.00(-100.0%) | $5.78 M(-43.4%) |
| June 2023 | - | $2.72 M(+580.8%) | $10.22 M(-38.7%) |
| Mar 2023 | - | $400.00 K(-85.0%) | $16.67 M(-54.3%) |
| Dec 2022 | $36.45 M(-239.5%) | $2.66 M(-40.1%) | $36.45 M(+24.2%) |
| Sept 2022 | - | $4.44 M(-51.6%) | $29.35 M(+60.8%) |
| June 2022 | - | $9.17 M(-54.5%) | $18.26 M(+59.1%) |
| Mar 2022 | - | $20.18 M(-554.5%) | $11.48 M(-143.9%) |
| Dec 2021 | -$26.12 M(-176.5%) | -$4.44 M(-33.3%) | -$26.12 M(+64.2%) |
| Sept 2021 | - | -$6.65 M(-378.0%) | -$15.91 M(+51.9%) |
| June 2021 | - | $2.39 M(-113.7%) | -$10.47 M(+76.4%) |
| Mar 2021 | - | -$17.43 M(-401.7%) | -$5.94 M(-117.4%) |
| Dec 2020 | $34.14 M(-193.4%) | $5.78 M(-575.7%) | $34.14 M(-3.2%) |
| Sept 2020 | - | -$1.21 M(-117.5%) | $35.25 M(+981.0%) |
| June 2020 | - | $6.93 M(-69.4%) | $3.26 M(-122.8%) |
| Mar 2020 | - | $22.65 M(+228.8%) | -$14.28 M(-60.9%) |
| Dec 2019 | -$36.56 M(+236.1%) | $6.89 M(-120.7%) | -$36.56 M(-34.0%) |
| Sept 2019 | - | -$33.21 M(+212.8%) | -$55.41 M(+382.2%) |
| June 2019 | - | -$10.62 M(-2961.7%) | -$11.49 M(+11.5%) |
| Mar 2019 | - | $371.00 K(-103.1%) | -$10.30 M(-5.3%) |
| Dec 2018 | -$10.88 M(+9.1%) | -$11.96 M(-211.6%) | -$10.88 M(+70.2%) |
| Sept 2018 | - | $10.71 M(-213.6%) | -$6.39 M(-63.8%) |
| June 2018 | - | -$9.43 M(+4544.3%) | -$17.64 M(+83.0%) |
| Mar 2018 | - | -$203.00 K(-97.3%) | -$9.64 M(-3.3%) |
| Dec 2017 | -$9.97 M(-651.1%) | -$7.47 M(+1299.8%) | -$9.97 M(+130.1%) |
| Sept 2017 | - | -$534.00 K(-62.5%) | -$4.33 M(-1.0%) |
| June 2017 | - | -$1.43 M(+165.9%) | -$4.38 M(+86.8%) |
| Mar 2017 | - | -$536.00 K(-70.8%) | -$2.34 M(-229.5%) |
| Dec 2016 | $1.81 M | -$1.84 M(+217.8%) | $1.81 M(-74.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2016 | - | -$578.00 K(-194.9%) | $7.03 M(-47.6%) |
| June 2016 | - | $609.00 K(-83.2%) | $13.40 M(+8.7%) |
| Mar 2016 | - | $3.62 M(+7.0%) | $12.33 M(+50.3%) |
| Dec 2015 | $8.20 M(-242.0%) | $3.38 M(-41.8%) | $8.20 M(+102.1%) |
| Sept 2015 | - | $5.80 M(-1352.9%) | $4.06 M(-176.7%) |
| June 2015 | - | -$463.00 K(-9.9%) | -$5.29 M(+4.9%) |
| Mar 2015 | - | -$514.00 K(-32.8%) | -$5.05 M(-12.6%) |
| Dec 2014 | -$5.78 M(-16.5%) | -$765.00 K(-78.5%) | -$5.78 M(-18.6%) |
| Sept 2014 | - | -$3.55 M(+1536.9%) | -$7.09 M(+40.5%) |
| June 2014 | - | -$217.00 K(-82.5%) | -$5.05 M(-42.6%) |
| Mar 2014 | - | -$1.24 M(-40.3%) | -$8.79 M(+27.0%) |
| Dec 2013 | -$6.92 M(-146.3%) | -$2.08 M(+38.1%) | -$6.92 M(-343.6%) |
| Sept 2013 | - | -$1.51 M(-61.9%) | $2.84 M(-68.3%) |
| June 2013 | - | -$3.96 M(-730.3%) | $8.96 M(-20.3%) |
| Mar 2013 | - | $628.00 K(-91.8%) | $11.24 M(-24.9%) |
| Dec 2012 | $14.96 M(-150.6%) | $7.68 M(+66.6%) | $14.96 M(+61.9%) |
| Sept 2012 | - | $4.61 M(-374.4%) | $9.24 M(-212.9%) |
| June 2012 | - | -$1.68 M(-138.6%) | -$8.18 M(-64.1%) |
| Mar 2012 | - | $4.35 M(+121.6%) | -$22.80 M(-22.9%) |
| Dec 2011 | -$29.58 M(-720.8%) | $1.96 M(-115.3%) | -$29.58 M(-6.5%) |
| Sept 2011 | - | -$12.81 M(-21.4%) | -$31.64 M(+81.2%) |
| June 2011 | - | -$16.29 M(+568.6%) | -$17.46 M(-730.9%) |
| Mar 2011 | - | -$2.44 M(+2337.0%) | $2.77 M(-41.9%) |
| Dec 2010 | $4.76 M(-44.7%) | -$100.00 K(-107.3%) | $4.76 M(-2.1%) |
| Sept 2010 | - | $1.37 M(-65.1%) | $4.87 M(+39.3%) |
| June 2010 | - | $3.93 M(-995.7%) | $3.49 M(-895.7%) |
| Mar 2010 | - | -$439.00 K | -$439.00 K |
| Dec 2009 | $8.62 M(-186.7%) | - | - |
| Dec 2008 | -$9.94 M | - | - |
FAQ
- What is AcelRx Pharmaceuticals annual cash flow from investing activities?
- What is the all time high annual CFI for AcelRx Pharmaceuticals?
- What is AcelRx Pharmaceuticals quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for AcelRx Pharmaceuticals?
- What is AcelRx Pharmaceuticals TTM cash flow from investing activities?
- What is the all time high TTM CFI for AcelRx Pharmaceuticals?
What is AcelRx Pharmaceuticals annual cash flow from investing activities?
The current annual CFI of ACRX is -$528.00 K
What is the all time high annual CFI for AcelRx Pharmaceuticals?
AcelRx Pharmaceuticals all-time high annual cash flow from investing activities is $36.45 M
What is AcelRx Pharmaceuticals quarterly cash flow from investing activities?
The current quarterly CFI of ACRX is -$3.65 M
What is the all time high quarterly CFI for AcelRx Pharmaceuticals?
AcelRx Pharmaceuticals all-time high quarterly cash flow from investing activities is $22.65 M
What is AcelRx Pharmaceuticals TTM cash flow from investing activities?
The current TTM CFI of ACRX is -$528.00 K
What is the all time high TTM CFI for AcelRx Pharmaceuticals?
AcelRx Pharmaceuticals all-time high TTM cash flow from investing activities is $36.45 M